AG
KERX

Aperio Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Aperio Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,226
Closed -$94K – 2272
2017
Q3 		$94K Buy
13,226
+382
+3% +$2.75K ﹤0.01% 2188
2017
Q2 		$93K Buy
12,844
+472
+4% +$2.95K ﹤0.01% 2185
2017
Q1 		$76K Buy
12,372
+1,010
+9% +$5.53K ﹤0.01% 2121
2016
Q4 		$67K Buy
11,362
+403
+4% +$2.2K ﹤0.01% 2098
2016
Q3 		$58K Buy
+10,959
New +$59.1K ﹤0.01% 2038
2015
Q4 		– Sell
-10,664
Closed -$38K – 2042
2015
Q3 		$38K Buy
+10,664
New +$71.4K ﹤0.01% 1914
2015
Q2 		– Sell
-10,539
Closed -$134K – 2054
2015
Q1 		$134K Sell
10,539
-5,535
-34% -$71.2K ﹤0.01% 1890
2014
Q4 		$227K Buy
16,074
+1,878
+13% +$29.1K ﹤0.01% 1670
2014
Q3 		$195K Buy
14,196
+1,071
+8% +$16.4K ﹤0.01% 1611
2014
Q2 		$202K Buy
+13,125
New +$186K ﹤0.01% 1615

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Aperio Group's KERX Position: Q4 2017 in Review

Aperio Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 13,226 shares — an estimated $94K sold.

Aperio Group first reported a position in KERX in Q2 2014 and held it in 10 quarters. The position peaked at $227K in Q4 2014. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Aperio Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Aperio Group sold 13,226 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $94K.
  • Aperio Group first reported a position in Keryx Biopharmaceuticals Inc in Q2 2014 and held it in 10 quarters.
  • Aperio Group's Keryx Biopharmaceuticals Inc position peaked at $227K in Q4 2014.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Aperio Group's 13F filing for Q4 2017, filed 2 Feb 2018.